Outlining Strategies for Effectively Implementing Integrative Oncology Care

Commentary
Video

Findings from clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.

In an interview with CancerNetwork®, Richard T. Lee, MD, a clinical professor and medical director of supportive and integrative medicine at City of Hope’s Center for Integrative Oncology, discussed strategies he employs to overcome challenges related to the integration of nonpharmaceutical approaches into conventional oncology practice.

He began by highlighting that challenges arise when implementing integrative oncology within a comprehensive cancer center to allow for interdisciplinary collaboration, but he listed strategies his practice employs to overcome them. One strategy, Lee claimed, is raising awareness and bolstering efforts to ensure that clinicians and patients are familiar with services associated with integrative oncology.

Another strategy, he asserted, is focusing on research. Pointing to prospective data from randomized controlled trials conducted in recent years as well as ongoing clinical research, he suggested that evidence can be drawn to inform the integration of these services into conventional standards for care. Furthermore, he stressed that City of Hope considers strategies for the successful integration of nonpharmaceutical approaches within its already existing supportive care services, emphasizing interdisciplinary collaboration to help coordinate care for patients who may have challenging or complex cancers.

Lee spoke with CancerNetwork at the 2025 Oncology Nursing Society Congress.

Transcript:

There have been many challenges [relating] to the implementation of integrative oncology services within a comprehensive cancer center to allow for more interdisciplinary collaboration. One of the strategies we have taken on at City of Hope is [focusing] on awareness and education of integrative oncology services. Surveys indicate that patients and clinicians are not familiar with the different services such as mind-body medicine, acupuncture, massage, and the field of integrative oncology.

A second strategy is to focus on the research. Over the last decade or more, there have been high-quality, prospective, randomized, controlled trials demonstrating the value and benefit for patients with cancer utilizing these types of services. Focusing on the evidence base that exists today as well as ongoing clinical trials is another great strategy.

Lastly, at City of Hope, we are thinking about how to interweave these types of services within [the] already great supportive care services that we provide. It is important to work closely with your colleagues in other areas such as supportive and palliative care medicine, social work, psychiatry, psychology, interventional pain, physical medicine, and rehabilitation. One of the things we have implemented is a weekly interdisciplinary team meeting in which all these individuals from different backgrounds, including nursing, social work, and others that I [previously] mentioned, are part of this team meeting to help coordinate care for [patients with] more complex and challenging [cases].

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Related Content